- Home
- BLW vs DRTS Comparison
BLW vs DRTS Comparison
Compare BLW & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLW | DRTS |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.2M | 607.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | BLW | DRTS |
|---|---|---|
| Price | $13.77 | $7.62 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 85.9K | ★ 460.3K |
| Earning Date | 01-01-0001 | 03-11-2026 |
| Dividend Yield | ★ 8.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.35 | $2.30 |
| 52 Week High | $14.26 | $7.89 |
Technical Indicators
Market Signals| Indicator | BLW | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 66.88 |
| Support Level | $13.72 | $6.23 |
| Resistance Level | $13.81 | $7.59 |
| Average True Range (ATR) | 0.07 | 0.65 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 41.97 | 88.02 |
Price Performance
Historical ComparisonAbout BLW Blackrock Limited Duration Income Trust
Blackrock Ltd Duration Income Trust is a diversified investment fund with an investment objective to provide current income and capital appreciation. The Fund's portfolio normally has an average portfolio duration of less than five years. The Fund may invest directly in such securities or synthetically through the use of derivatives.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.